SG11202009853VA - Growth differentiation factor 15 agonist compounds and methods of using the same - Google Patents

Growth differentiation factor 15 agonist compounds and methods of using the same

Info

Publication number
SG11202009853VA
SG11202009853VA SG11202009853VA SG11202009853VA SG11202009853VA SG 11202009853V A SG11202009853V A SG 11202009853VA SG 11202009853V A SG11202009853V A SG 11202009853VA SG 11202009853V A SG11202009853V A SG 11202009853VA SG 11202009853V A SG11202009853V A SG 11202009853VA
Authority
SG
Singapore
Prior art keywords
methods
same
differentiation factor
agonist compounds
growth differentiation
Prior art date
Application number
SG11202009853VA
Inventor
Malgorzata Donata Gonciarz
Victor H Obungu
Richard Todd Pickard
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202009853VA publication Critical patent/SG11202009853VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202009853VA 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same SG11202009853VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06
PCT/US2019/024756 WO2019195091A1 (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202009853VA true SG11202009853VA (en) 2020-11-27

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009853VA SG11202009853VA (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Country Status (27)

Country Link
US (1) US11104711B2 (en)
EP (1) EP3774860B1 (en)
JP (1) JP7064618B2 (en)
KR (1) KR102501922B1 (en)
CN (1) CN112004821B (en)
AR (1) AR115021A1 (en)
AU (1) AU2019248535B2 (en)
BR (1) BR112020017256A2 (en)
CA (1) CA3096375C (en)
CL (1) CL2020002564A1 (en)
CO (1) CO2020012403A2 (en)
CR (1) CR20200454A (en)
DO (1) DOP2020000157A (en)
EA (1) EA202092084A1 (en)
EC (1) ECSP20062930A (en)
ES (1) ES2937049T3 (en)
IL (1) IL276980A (en)
JO (1) JOP20200252B1 (en)
MA (1) MA52228A (en)
MX (1) MX2020010370A (en)
PE (1) PE20212133A1 (en)
PH (1) PH12020551656A1 (en)
SG (1) SG11202009853VA (en)
TW (1) TWI724392B (en)
UA (1) UA127545C2 (en)
WO (1) WO2019195091A1 (en)
ZA (1) ZA202005385B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
AU2014296107B2 (en) 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
PE20201350A1 (en) 2018-04-09 2020-11-30 Amgen Inc FUSION PROTEINS OF THE GROWTH DIFFERENTIATION FACTOR 15
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
MX2022004311A (en) 2019-10-15 2022-05-10 Lilly Co Eli Recombinantly engineered, lipase/esterase-deficient mammalian cell lines.
AU2022333099A1 (en) 2021-08-24 2024-02-08 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and uses thereof
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (en) * 2001-07-05 2007-01-15 Univ Zuerich A pharmaceutical composition suitable for use in orthopedics and dentistry
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EA024755B1 (en) * 2010-05-21 2016-10-31 ИксЭль-ПРОТЕИН ГМБХ Biosynthetic proline/alanine random coil polypeptides and their uses
DK2670847T3 (en) * 2011-02-03 2017-01-16 Xoma Technology Ltd Methods and Materials for Improving Functional Protein Expression in Bacteria
BR112014018575A2 (en) * 2012-01-26 2017-07-04 Amgen Inc Growth Differentiation Factor 15 Polypeptides (gdf-15)
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2896076C (en) * 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
RU2704285C2 (en) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Compositions and methods of using for treating metabolic disorders
AU2014296215A1 (en) 2013-07-31 2016-02-11 Amgen Inc. Stabilization of Fc-containing polypeptides
AU2014296107B2 (en) * 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
WO2015200080A1 (en) 2014-06-23 2015-12-30 Novartis Ag Site specific protein modifications
JP6696915B2 (en) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー/エス MIC-1 fusion protein and uses thereof
CR20170027A (en) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc COMPOSITIONS AND METHODS OF USE TO TREAT METABOLIC DISORDERS
WO2016069925A1 (en) 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
TWI703161B (en) * 2014-10-31 2020-09-01 美商Ngm生物製藥公司 Compositions and methods of use for treating metabolic disorders
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
TW201708249A (en) 2015-04-02 2017-03-01 健生生物科技公司 Protoxin-II variants and methods of use
JP6946304B2 (en) * 2015-12-22 2021-10-06 ノバルティス アーゲー Methods of Treating or Relieving Metabolic Disorders Using Proliferative Differentiation Factor 15 (GDF-15)
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP2019510739A (en) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー GFRAL receptor therapy
WO2017147743A1 (en) 2016-02-29 2017-09-08 华为技术有限公司 Video optimization method, user equipment unit and network equipment unit
EP3423097A4 (en) 2016-03-04 2019-08-21 NGM Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
DOP2020000157A (en) 2020-09-15
UA127545C2 (en) 2023-10-04
US11104711B2 (en) 2021-08-31
MA52228A (en) 2021-02-17
CO2020012403A2 (en) 2020-10-30
ES2937049T3 (en) 2023-03-23
EA202092084A1 (en) 2021-01-27
MX2020010370A (en) 2021-01-08
PE20212133A1 (en) 2021-11-05
KR20200128091A (en) 2020-11-11
JP7064618B2 (en) 2022-05-10
JOP20200252A1 (en) 2020-10-04
CN112004821B (en) 2024-01-02
ZA202005385B (en) 2022-09-28
CA3096375C (en) 2023-09-12
PH12020551656A1 (en) 2021-07-26
CL2020002564A1 (en) 2021-01-29
JP2021517584A (en) 2021-07-26
JOP20200252B1 (en) 2023-09-17
CA3096375A1 (en) 2019-10-10
KR102501922B1 (en) 2023-02-23
BR112020017256A2 (en) 2020-12-22
ECSP20062930A (en) 2020-11-30
EP3774860B1 (en) 2022-12-28
AU2019248535A1 (en) 2020-09-10
AR115021A1 (en) 2020-11-18
AU2019248535B2 (en) 2021-09-02
CN112004821A (en) 2020-11-27
TW201946661A (en) 2019-12-16
TWI724392B (en) 2021-04-11
EP3774860A1 (en) 2021-02-17
US20190309033A1 (en) 2019-10-10
WO2019195091A1 (en) 2019-10-10
IL276980A (en) 2020-10-29
CR20200454A (en) 2020-11-18

Similar Documents

Publication Publication Date Title
ZA202005385B (en) Growth differentiation factor 15 agonist compounds and methods of using the same
ZA202001447B (en) M-diamide compound and preparation method therefor and use thereof
ZA202106625B (en) Beta adrenergic agonist and methods of using the same
SG11202108398YA (en) Anti-claudin 18 antibodies and methods of use thereof
IL289350A (en) Beta adrenergic agonist and methods of using the same
EP4002993A4 (en) Morphogenic regulators and methods of using the same
SG11202100818RA (en) Tlr7/8 antagonists and uses thereof
IL281015A (en) Methods and compositions for the modification of plants
IL277842A (en) Growth differentiation factor 15 fusion proteins
EP3630046A4 (en) Anti-doublecortin-like kinase 1 antibodies and methods of use
GB201820450D0 (en) Compound and its use for the treatment of alpha1-antitryspin deficiency
IL276148A (en) Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP3731867A4 (en) Anti-lrp5/6 antibodies and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
EP3768408A4 (en) Halloysite-based nanocomposites and methods of making and using the same
IL288082A (en) Amide compounds and preparation method therefor and use thereof
EP3899292C0 (en) Screw with milling-ribs for countersinking the screw and use of the screw
EP3765449A4 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
IL279579A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
EP3724933A4 (en) Superconducting compounds and methods for making the same
IL286485A (en) Pi4-kinase inhibitors and methods of using the same
EP3837239A4 (en) Process for the preparation of solriamfetol and salt thereof
IL284069A (en) Anti-angptl3/8 complex antibodies and methods of using the same
EP3986436A4 (en) Antagonists of camkii-delta 9 and uses thereof
EP3987658A4 (en) Adjustable inductor and method of using the same